Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).
Mottet, N. et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. EAU https://uroweb.org/guidelines/prostate-cancer (2020).
Wallitt, K. L. et al. Clinical PET imaging in prostate cancer. RadioGraphics 37, 1512–1536 (2017).
Jadvar, H. Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET. Nat. Rev. Urol. 6, 317–323 (2009).
Jadvar, H. Is there use for FDG-PET in prostate cancer? Semin. Nucl. Med. 46, 502–506 (2016).
Horoszewicz, J. S. et al. The LNCaP cell line — a new model for studies on human prostatic carcinoma. Prog. Clin. Biol. Res. 37, 115–132 (1980).
Horoszewicz, J. S., Kawinski, E. & Murphy, G. P. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 7, 927–935 (1987).
Wynant, G. E. et al. Immunoscintigraphy of prostatic cancer: preliminary results with 111In-labeled monoclonal antibody 7E11-C5.3 (CYT-356). Prostate 18, 229–241 (1991).
Robinson, M. B., Blakely, R. D., Couto, R. & Coyle, J. T. Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain. J. Biol. Chem. 262, 14498–14506 (1987).
Kozikowski, A. P. et al. Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase). J. Med. Chem. 44, 298–301 (2001).
Maurer, T., Eiber, M., Schwaiger, M. & Gschwend, J. E. Current use of PSMA-PET in prostate cancer management. Nat. Rev. Urol. 13, 226–235 (2016).
Lawhn-Heath, C. et al. Prostate-specific membrane antigen PET in prostate cancer. Radiology 299, 248–260 (2021).
Siva, S. et al. Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer. Nat. Rev. Urol. 17, 107–118 (2020).
van Leeuwen, F. W. B. et al. Technologies for image-guided surgery for managing lymphatic metastases in prostate cancer. Nat. Rev. Urol. 16, 159–171 (2019).
Wright, G. L. Jr, Haley, C., Beckett, M. L. & Schellhammer, P. F. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol. Oncol. 1, 18–28 (1995).
O’Keefe, D. S. et al. Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. Biochim. Biophys. Acta 1443, 113–127 (1998).
DeMarzo, A. M., Nelson, W. G., Isaacs, W. B. & Epstein, J. I. Pathological and molecular aspects of prostate cancer. Lancet 361, 955–964 (2003).
Kinoshita, Y. et al. Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J. Surg. 30, 628–636 (2006).
Silver, D. A., Pellicer, I., Fair, W. R., Heston, W. D. & Cordon-Cardo, C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. 3, 81–85 (1997).
Ferreira, G., Iravani, A., Hofman, M. S. & Hicks, R. J. Intra-individual comparison of 68Ga-PSMA-11 and 18F-DCFPyL normal-organ biodistribution. Cancer Imaging 19, 23 (2019).
Israeli, R. S., Powell, C. T., Fair, W. R. & Heston, W. D. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. 53, 227–230 (1993).
Barinka, C. et al. Selection and characterization of Anticalins targeting human prostate-specific membrane antigen (PSMA). Protein Eng. Des. Sel. 29, 105–115 (2016).
Pinto, J. T. et al. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin. Cancer Res. 2, 1445–1451 (1996).
Paschalis, A. et al. Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer. Eur. Urol. 76, 469–478 (2019).
Bostwick, D. G., Pacelli, A., Blute, M., Roche, P. & Murphy, G. P. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 82, 2256–2261 (1998).
Mannweiler, S. et al. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol. Oncol. Res. 15, 167–172 (2009).
Kaittanis, C. et al. Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors. J. Exp. Med. 215, 159–175 (2018).
Caromile, L. A. & Shapiro, L. H. PSMA redirects MAPK to PI3K-AKT signaling to promote prostate cancer progression. Mol. Cell. Oncol. 4, e1321168 (2017).
Shorning, B. Y., Dass, M. S., Smalley, M. J. & Pearson, H. B. The PI3K-AKT-mTOR pathway and prostate cancer: at the crossroads of AR, MAPK, and WNT signaling. Int. J. Mol. Sci. 21, 4507 (2020).
Xu, L. et al. Screening and identification of significant genes related to tumor metastasis and PSMA in prostate cancer using microarray analysis. Oncol. Rep. 30, 1920–1928 (2013).
Wu, J. et al. A novel fully human antibody targeting extracellular domain of PSMA inhibits tumor growth in prostate cancer. Mol. Cancer Ther. 18, 1289–1301 (2019).
Su, Y. et al. PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth. Cancer Lett. 338, 282–291 (2013).
Kuroda, K. & Liu, H. The proteasome inhibitor, bortezomib, induces prostate cancer cell death by suppressing the expression of prostate-specific membrane antigen, as well as androgen receptor. Int. J. Oncol. 54, 1357–1366 (2019).
Weidle, U. H., Epp, A., Birzele, F. & Brinkmann, U. The functional role of prostate cancer metastasis-related Micro-RNAs. Cancer Genomics Proteom. 16, 1–19 (2019).
Vummidi Giridhar, P., Williams, K., VonHandorf, A. P., Deford, P. L. & Kasper, S. Constant degradation of the androgen receptor by MDM2 conserves prostate cancer stem cell integrity. Cancer Res. 79, 1124–1137 (2019).
Zhou, Y., Bolton, E. C. & Jones, J. O. Androgens and androgen receptor signaling in prostate tumorigenesis. J. Mol. Endocrinol. 54, R15–R29 (2015).
Shore, N. D., Abrahamsson, P. A., Anderson, J., Crawford, E. D. & Lange, P. New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists. Prostate Cancer Prostatic Dis. 16, 7–15 (2013).
Bakht, M. K. et al. Influence of androgen deprivation therapy on the uptake of PSMA-targeted agents: emerging opportunities and challenges. Nucl. Med. Mol. Imaging 51, 202–211 (2017).
Vaz, S. et al. Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients. Eur. J. Nucl. Med. Mol. Imaging 47, 9–15 (2020).
Roy, J. et al. Monitoring PSMA responses to ADT in prostate cancer patient-derived xenograft mouse models using [18F]DCFPyL PET imaging. Mol. Imaging Biol. 23, 745–755 (2021).
Hope, T. A. et al. 68Ga-PSMA-11 PET imaging of response to androgen receptor inhibition: first human experience. J. Nucl. Med. 58, 81–84 (2017).
Mei, R. et al. Androgen deprivation therapy and its modulation of PSMA expression in prostate cancer: mini review and case series of patients studied with sequential [68Ga]-Ga-PSMA-11 PET/CT. Clin. Transl. Imaging 9, 215–220 (2021).
Leitsmann, C. et al. Enhancing PSMA-uptake with androgen deprivation therapy — a new way to detect prostate cancer metastases? Int. Braz. J. Urol. 45, 459–467 (2019).
Ettala, O. et al. Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated with 68Ga-PSMA-11 PET/MRI in men with treatment-naïve prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 47, 665–673 (2020).
Liu, T., Wu, L. Y., Fulton, M. D., Johnson, J. M. & Berkman, C. E. Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells. Int. J. Oncol. 41, 2087–2092 (2012).
Afshar-Oromieh, A. et al. Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 45, 2045–2054 (2018).
Hoberück, S. et al. [68Ga]Ga-PSMA-11 PET before and after initial long-term androgen deprivation in patients with newly diagnosed prostate cancer: a retrospective single-center study. EJNMMI Res. 10, 135 (2020).
Wright, G. L. Jr et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48, 326–334 (1996).
Chen, M. et al. Can 68Ga-PSMA-11 positron emission tomography/computerized tomography predict pathological response of primary prostate cancer to neoadjuvant androgen deprivation therapy? A pilot study. J. Urol. 205, 1082–1089 (2021).
Murga, J. D. et al. Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer. Prostate 75, 242–254 (2015).
Evans, M. J. et al. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc. Natl Acad. Sci. USA 108, 9578–9582 (2011).
Emmett, L. et al. Rapid modulation of PSMA expression by androgen deprivation: serial 68Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade. J. Nucl. Med. 60, 950–954 (2019).
Minner, S. et al. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate 71, 281–288 (2011).
留言 (0)